Neumora治疗药物的库存下降超过80%, 因为它的抑郁药物未能进行关键试验。 Neumora Therapeutics' stock drops over 80% as its depression drug fails key trial.

Neumora Therapeutics 的股价在其抑郁症药物 navacaprant 在重度抑郁症的关键 3 期试验失败后暴跌超过 80%。 Neumora Therapeutics' stock plummeted over 80% after its depression drug, navacaprant, failed a key Phase 3 trial for major depressive disorder. 虽然该药物在减少抑郁症症状方面没有显著改善,但发现该药物是安全的,而且经良好处理。 While the drug did not show significant improvement in reducing depressive symptoms, it was found safe and well-tolerated. Neumora计划继续进行进一步分析和更多试验,预期在即将举行的保健会议上提供最新情况。 Neumora plans to continue with further analyses and additional trials, with updates expected at an upcoming healthcare conference.